EOLS (Evolus) Short Interest


EOLS Evolus Inc EOLS
71 GF Score
Price $6.97
GF Value $13.59
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Evolus Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

EOLS vs EBS, ELTP, AQST: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolus Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Short Interest distribution charts can be found below:

* The bar in red indicates where Evolus's Short Interest falls into.


EOLS
71GF Score
Evolus Inc EOLS
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Evolus (EOLS) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of $6.97 is trading 48.7% below its estimated GF Value™ of $13.59. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for EOLS:

  • Short Interest:
  • GF Value™: $13.59 vs. price of $6.97 (48.7% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolus Business Description

Other Exchanges EVL:Germany
Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
71GF Score

Get the complete analysis for EOLS

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.97
Price
$13.59
GF Value